Findings at week 52 per treatment group
| First-line IFX | Conventional | P value | |
| wPCDAI, median (IQR) | 7.5 (0–15) | 10 (0–17.5) | 0.476 |
| Clinical remission, n (%) | 33/47 (70) | 26/46 (57) | 0.420 |
| Clinical remission in patients on immunomodulator monotherapy, n (%) | 22/29 (76) | 12/18 (67) | 0.958 |
| Endoscopic remission, n (%)* | 5/18 (28) | 5/14 (36) | 0.630 |
| SES-CD, median (IQR) | 7 (2–7) | 6 (0–10) | 0.961 |
| Fcal <100 µg/g, n (%) | 17/48 (35) | 9/47 (19) | 0.120 |
Clinical remission is defined as a wPCDAI <12.5. Endoscopic remission was defined as a SES-CD <3. The group of patients on immunomodulator monotherapy comprised patients on azathioprine (n=46) and methotrexate (n=1). Baseline characteristics of these patients are similar (online supplemental table 2C).
*Eighteen FL-IFX patients and 14 conventionally treated patients consented for endoscopy at week 52.
Fcal, faecal calprotectin; IFX, infliximab; SES-CD, Simple Endoscopic Score for Crohn’s Disease; wPCDAI, weighted Paediatric Crohn’s Disease Activity Index.